Comparative Pharmacology
Head-to-head clinical analysis: ANTITUSSIVE versus DEXTROMETHORPHAN POLISTIREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTITUSSIVE versus DEXTROMETHORPHAN POLISTIREX.
ANTITUSSIVE vs DEXTROMETHORPHAN POLISTIREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 3-6 hours in adults; prolonged in renal impairment (up to 12-18 hours).
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 60-80% of elimination, with biliary/fecal excretion contributing 15-25%.
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
Category C
Category C
Antitussive
Antitussive